Glaucoma Pipeline Highlights – 2017 Update

1. Glaucoma Pipeline by Stages

2. Glaucoma Pipeline by Drug Class

3. Glaucoma Pipeline by Company

4. Glaucoma Phase 3 Clinical Trial Insights

5. Glaucoma Phase 2 Clinical Trial Insights

6. Glaucoma Phase 1 Clinical Trial Insights

7. Glaucoma Preclinical Research Insights

8. Glaucoma Discovery Stage Insights

9. Appendix

10. Research Methodology

LIST OF TABLES

Table 1: Glaucoma Phase 3 Clinical Trials, 2017

Table 2: Glaucoma Phase 2 Clinical Trials, 2017

Table 3: Glaucoma Phase 1 Clinical Trials, 2017

Table 4: Glaucoma Preclinical Research, 2017

Table 5: Glaucoma Discovery Stage, 2017

LIST OF FIGURES

Figure 1: Glaucoma Pipeline Molecules by Clinical Trials Stage, 2017

Figure 2: Glaucoma Pipeline Molecules by Drug Class, 2017

Figure 3: Glaucoma Pipeline Molecules by Company, 2017

Figure 4: Glaucoma Phase 3 Clinical Trial Highlights, 2017

Figure 5: Glaucoma Phase 2 Clinical Trial Highlights, 2017

Figure 6: Glaucoma Phase 1 Clinical Trial Highlights, 2017

Figure 7: Glaucoma Preclinical Research Highlights, 2017

Figure 8: Glaucoma Discovery Stage Highlights, 2017

Glaucoma Pipeline Highlights – 2017 Update

The latest report from Fore Pharma, Glaucoma Pipeline Highlights – 2017 Update, provides most up-to-date information on key pipeline products in the global Glaucoma market. It covers emerging therapies for Glaucoma in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:
The report provides Glaucoma pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:
The report provides Glaucoma pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:
The report provides Glaucoma pipeline products by the company.

Short-term Launch Highlights:
Find out which Glaucoma pipeline products will be launched in the US and Ex-US till 2020.

SUMMARY:

• Glaucoma phase 3 clinical trial pipeline products
• Glaucoma phase 2 clinical trial pipeline products
• Glaucoma phase 1 clinical trial pipeline products
• Glaucoma preclinical research pipeline products
• Glaucoma discovery stage pipeline products
• Glaucoma pipeline products short-term launch highlights